Trials / Active Not Recruiting
Active Not RecruitingNCT03865082
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Idera Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.
Detailed description
This is a Phase 2, open-label,multi-center, multicohort study of intratumoral tilsotolimod in combination with nivolumab and ipilimumab for the treatment of specific solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tilsotolimod | 9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7. |
| DRUG | Nivolumab | Specified dose on specified days. |
| DRUG | Ipilimumab | Specified dose on specified days. |
Timeline
- Start date
- 2019-10-29
- Primary completion
- 2022-03-01
- Completion
- 2022-04-01
- First posted
- 2019-03-06
- Last updated
- 2022-02-17
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03865082. Inclusion in this directory is not an endorsement.